Key result
Abciximab provides superior value in high-risk PCI, while alternative GP IIb/IIIa inhibitors show similar costs.
Why the study?
The cost-effectiveness and number needed to treat of platelet glycoprotein IIb/IIIa inhibitors in PCI and acute coronary syndromes were not well characterized across pivotal trials.
Answers are grounded in this paper and cite their sources.
This retrospective review and analysis of pivotal clinical trials compared acquisition costs and outcomes of platelet glycoprotein IIb/IIIa inhibitors. Absolute reduction in the number of deaths and nonfatal myocardial infarctions at 30 days, number of patients that need to be treated to prevent one event, and drug costs expended to prevent one event were assessed. In patients undergoing percutaneous coronary intervention (PCI), abciximab is the better value, especially in high-risk patients. In those with unstable angina and non-Q wave myocardial infarction, costs of eptifibatide and tirofiban were not significantly different, but the cost of tirofiban was more variable. These agents have the potential to be cost-effective if administered to populations at high risk for adverse outcomes of acute coronary syndromes or PCI. Prospective methods to identify these high-risk patients are being developed.
No takes yet. Share an insight, caveat, or question.
Dawn Bell (1999) conducted a review in Percutaneous coronary intervention and acute coronary syndromes. Platelet glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) was evaluated on Deaths and nonfatal myocardial infarctions at 30 days, number needed to treat, and drug costs expended to prevent one event.
Synapse has enriched 10 related papers. Consider them for comparative context: